Low-molecular-weight collagen peptide · VAS pain in early knee osteoarthritis — Evidence Check

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Evidence conditionSelected question and original subclaim valuesRequired	The original selected Reduced VAS pain subclaim, grade D and note are retained. Parent C50 and original axes concern the parent verdict. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Subclaim score, status and axes are absent; parent values are not assigned to the subclaim. Existing-content review remains incomplete.	Selected question grade/note, parent context and presence of score/status/axes	Proposed updating research linking original-question scope to additional materials; no new search, calculation or trial was performed.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionEarly knee osteoarthritis populationRequired	The original population was 80 adults with Kellgren–Lawrence grade 1–2 early knee osteoarthritis. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Detailed eligibility, age/symptoms, baseline pain, comorbidities and group-specific characteristics are unverified. Existing-content review remains incomplete.	Actual disease stage, recruitment criteria and baseline characteristics	Proposed follow-up research on applicability and heterogeneity within the same population scope; no new search, calculation or trial was performed.
3	Partly verified	Full text not readStored summary read	N03 · Evidence conditionSpecific low-molecular-weight peptideRequired	The specific tested low-molecular-weight collagen peptide at 3 g daily is retained; it does not become an effect of all oral collagen or other compositions. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Molecular-weight distribution, source/manufacturing, detailed composition, batches and actual individual exposure are unverified. Existing-content review remains incomplete.	Identity, composition and exposure of the tested preparation	Proposed follow-up research distinguishing formulation differences and result attribution; no new search, calculation or trial was performed.
4	Partly verified	Full text not readStored summary read	N04 · Evidence conditionPlacebo, manufacturing and control conditionsRequired	The original double-blind placebo-controlled design and account that NEWTREE manufactured product and placebo are retained. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Placebo ingredients, sensory matching, co-exposure and equality of actual conditions between groups are unverified. Existing-content review remains incomplete.	Actual placebo identity, matching and accompanying conditions	Proposed follow-up research on control conditions and measurement bias; no new search, calculation or trial was performed.
5	Partly verified	Full text not readStored summary read	N05 · Evidence conditionResearch exposure: 3 g daily for 180 daysRequired	The original research condition was 3 g daily for 180 days; no new intake instructions, product recommendations or treatment methods are provided. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Individual exposure, adherence measurement, discontinuation/changes and results for other durations/doses are unverified. Existing-content review remains incomplete.	Original dose/duration and actual exposure/discontinuation	Proposed follow-up research distinguishing dose/duration-specific applicability; no new search, calculation or trial was performed.
6	Partly verified	Full text not readStored summary read	N06 · Evidence condition80 randomized; 40/40Required	Original allocation denominators of 80 participants randomized, 40 per group, are retained. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Original allocation generation/concealment, stratification, responsible roles and implementation remain unread. The two groups are not separate trials. Existing-content review remains incomplete.	Allocation unit, generation/concealment and group denominators	Proposed follow-up research on allocation procedures and actual populations; no new search, calculation or trial was performed.
7	Partly verified	Full text not readStored summary read	N07 · Evidence conditionDouble blinding and measurement rolesRequired	The original double-blind design is retained. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Role-specific masking, maintenance/unmasking, sensory matching and measurement/analysis procedures are unverified. The design label does not certify absence of actual bias. Existing-content review remains incomplete.	Masking of participants, clinical/research staff and outcome assessment/analysis	Proposed follow-up research on maintained masking and outcome measurement; no new search, calculation or trial was performed.
8	Partly verified	Full text not readStored summary read	N08 · Evidence conditionVAS pain scaleRequired	The selected existing question is reduced VAS pain; its subclaim grade D and note are retained. It is a different scale from WOMAC pain and WOMAC total. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. VAS form, range/score units, assessment procedures, measurement conditions and original individual data are unverified. Existing-content review remains incomplete.	Definition, units, range and measurement conditions of the selected VAS	Proposed follow-up research using the same scale and measurement scope; no new search, calculation or trial was performed.
9	Partly verified	Full text not readStored summary read	N09 · Evidence conditionVAS assessment timing and change versus final valuesRequired	The original context of VAS measured concurrently in the 180-day trial is retained. The prespecified day-180 WOMAC change timing and estimand are not assigned to VAS. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Exact VAS visits/assessment windows, change versus final values, repeated measurements and group-specific observed denominators are unverified. Existing-content review remains incomplete.	Actual VAS timing, change/final values and observed population	Proposed follow-up research distinguishing scales, timing and change/final values; no new search, calculation or trial was performed.
10	Partly verified	Full text not readStored summary read	N10 · Evidence conditionVAS P=.299: original null-result accountRequired	The selected note and original result that the between-group comparison was null, P=.299, are retained. No new effect size, CI, exact zero effect or equivalence is created. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Group-specific VAS values, effect estimate, direction, units, CI, model and test details are unverified. Existing-content review remains incomplete.	VAS between-group testing distinguished from estimation and precision	Proposed follow-up research distinguishing nonsignificance from uncertainty; no new search, calculation or trial was performed.
11	Partly verified	Full text not readStored summary read	N11 · Evidence conditionVAS analysis denominators and ITT/PPRequired	The trial randomized 80 participants and had a primary efficacy PP population of 60, but exact VAS analysis/observed denominators are separately unverified. Neither the safety population of 80 nor WOMAC PP results are automatically transferred to VAS. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. VAS group-specific PP/ITT, completed/observed denominators, exclusions, missingness handling and sensitivity analyses are unverified. Existing-content review remains incomplete.	Actual VAS analysis population and group-specific denominators	Proposed follow-up research distinguishing outcome-specific populations and missingness assumptions; no new search, calculation or trial was performed.
12	Unverified	Full text not readStored summary read	N12 · Evidence conditionVAS important difference and success thresholdRequired	WOMAC-related post hoc SMD 0.46/external AAOS 0.39 interpretations are not transferred into a prespecified VAS success threshold or confirmation of clinical nullity. S01	The currently required information is unverified in the preserved summary. Prespecified VAS important difference, estimand/CI, planned power and clinical importance are unverified. Existing-content review remains incomplete.	Prespecified VAS important difference, precision and interpretation scope	Proposed follow-up research on scale-specific important differences and uncertainty; no new search, calculation or trial was performed.
13	Partly verified	Full text not readStored summary read	N13 · Evidence conditionPositive WOMAC: a separate resultRequired	Prespecified day-180 WOMAC pain change in the PP population of 60 was -1.90±4.14 versus +0.61±3.97, with an original approximate between-group difference of -2.51 points/P=.006. This is not transferred into improved VAS pain. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Scale-specific analysis denominators, covariance, measurement/test correspondence and details of disagreement between results are unverified. The two scales are not counted as independent replications. Existing-content review remains incomplete.	Relationship between WOMAC and VAS results/hierarchy in the same report	Proposed follow-up research distinguishing scale-specific results and disagreement; no new search, calculation or trial was performed.
14	Partly verified	Full text not readStored summary read	N14 · Evidence conditionPP 60: selection criteriaRequired	The original primary efficacy population was 60/80 PP participants with at least 80% adherence and no major deviation, distinct from the safety population of 80 and randomized 40/40. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Group-specific PP denominators, time-specific observations, deviation/attrition reasons and the selected question’s actual analysis population are not verified in detail. Existing-content review remains incomplete.	Inclusion criteria and group-specific denominators for the primary PP efficacy population	Proposed follow-up research on differences between PP-selected and randomized populations; no new search, calculation or trial was performed.
15	Partly verified	Full text not readStored summary read	N15 · Evidence condition20/80 (25%) excludedRequired	Original exclusion of 20/80 (25%) is retained; exclusions are not all relabeled as follow-up losses or a single reason. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Group-specific adherence/deviation versus missingness/discontinuation, missingness assumptions and sensitivity results are unverified. Existing-content review remains incomplete.	Reasons, group distribution and outcome implications of efficacy exclusions	Proposed follow-up research on uncertainty under exclusion/missingness assumptions; no new search, calculation or trial was performed.
16	Partly verified	Full text not readStored summary read	N16 · Evidence conditionITT described as the same directionRequired	The original account describes ITT only as the same direction; this does not fill equal effect sizes, significance, CI or confirmation of PP results. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Selected-outcome ITT values, group denominators, model, missingness handling and CI/P are unverified. Existing-content review remains incomplete.	ITT population, estimand, precision and relationship to PP	Proposed follow-up research distinguishing different ITT/PP analysis scopes; no new search, calculation or trial was performed.
17	Partly verified	Full text not readStored summary read	N17 · Evidence conditionPP Kellgren–Lawrence imbalanceRequired	The original account of PP Kellgren–Lawrence grade-distribution imbalance, P=.037, is retained. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Group-specific stage distributions, pain/other baseline differences, adjustment and sensitivity materials are unverified. No adjusted effect is newly calculated. Existing-content review remains incomplete.	Baseline disease-stage distribution and adjustment in the PP population	Proposed follow-up research on baseline imbalance and population selection; no new search, calculation or trial was performed.
18	Unverified	Full text not readStored summary read	N18 · Evidence conditionCo-exposure and adherenceRequired	The PP inclusion criterion of at least 80% adherence is distinguished from actual participant-specific adherence. S01	The currently required information is unverified in the preserved summary. Concurrent analgesics, rehabilitation/activity, other supplements, rescue medication and actual adherence measurement/discontinuation are unverified. No new treatment/exercise methods are created. Existing-content review remains incomplete.	Pain-related co-exposure and adherence/change records	Proposed follow-up research on co-exposure and attribution of product results; no new search, calculation or trial was performed.
19	Partly verified	Full text not readStored summary read	N19 · Evidence conditionKCT and prospective registrationRequired	The original registration identifier KCT0005507 and prospective-registration account are retained; identifier format is not changed and no new registration status is certified. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Registration full text, change history, protocol/SAP and comparison with actual recruitment/analysis timing remain unread. Existing-content review remains incomplete.	Original registration identity, prespecified endpoints/analyses and changes	Proposed follow-up research linking prespecified plans with reported results; no new search, calculation or trial was performed.
20	Partly verified	Full text not readStored summary read	N20 · Evidence conditionTwo pain scales and prespecified hierarchyRequired	The prespecified primary endpoint was baseline-to-day-180 WOMAC pain change; concurrent VAS was a separate pain outcome. The original false marker for split coprimary results is not converted into a new coprimary declaration. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. VAS prespecified hierarchy, actual assessment windows, multiple outcome/time-point tests, multiplicity handling and SAP are unverified. Existing-content review remains incomplete.	Prespecified endpoint, timing and multiplicity scope for WOMAC pain and VAS	Proposed follow-up research distinguishing endpoint estimates and prespecified hierarchy; no new search, calculation or trial was performed.
21	Partly verified	Full text not readStored summary read	N21 · Evidence conditionSample size: 10-point WOMAC total differenceRequired	The original sample-size calculation assumed a 10-point WOMAC total difference rather than WOMAC pain; those 10 points do not become a prespecified pain-success threshold. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Planned variance, power, attrition assumptions and precision scope for pain/VAS are unverified. Existing-content review remains incomplete.	Sample-size planning endpoint/assumptions and selected result	Proposed follow-up research on planning assumptions and actual endpoints; no new search, calculation or trial was performed.
22	Partly verified	Full text not readStored summary read	N22 · Evidence conditionPost hoc SMD and external important differenceRequired	The authors’ post hoc interpretation that observed SMD 0.46 exceeded external AAOS minimum difference 0.39 is retained as original history; the original account states no clinical-success threshold was prespecified. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. SMD definition, corresponding endpoint, denominator, CI and population/scale/applicability scope of the external criterion are unverified. No new standardized effect or success certification is made. Existing-content review remains incomplete.	Prespecified success threshold versus post hoc interpretation/external criteria	Proposed follow-up research distinguishing important differences from post hoc interpretation; no new search, calculation or trial was performed.
23	Partly verified	Full text not readStored summary read	N23 · Evidence conditionOne trial, sibling sheets and independenceRequired	The same Kim DU 2025 report, KCT0005507, 80 participants/PP60, two scales, time points and sibling sheets are not totaled as new independent trials/participants. Original R1/I0 are historical parent-verdict context. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. External comparison of actual unique trial/participant correspondence and independent replication is unverified. Existing-content review remains incomplete.	Report–trial–population–outcome relationships and independent replication materials	Proposed follow-up research distinguishing separate evidence for the same formulation/question; no new search, calculation or trial was performed.
24	Partly verified	Full text not readStored summary read	N24 · Evidence conditionResearch and publication supportRequired	The original account that NEWTREE Co., Ltd. supported research and publication is retained. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Original support contracts, amounts, individual costs/roles and disclosures remain unread; publication support does not establish every cost item was verified. Existing-content review remains incomplete.	Separate funding and research/publication support roles	Proposed follow-up research on support roles and outcome reporting; no new search, calculation or trial was performed.
25	Partly verified	Full text not readStored summary read	N25 · Evidence conditionProduct and placebo manufacturingRequired	The original account that NEWTREE manufactured tested product and placebo is retained. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Manufacturing/batches, supply contracts, whether provision was free and role details are unverified. Manufacturing alone does not fill free-support details. Existing-content review remains incomplete.	Individual records of manufacturing and free-product support/batches	Proposed follow-up research distinguishing manufacturing from supply roles; no new search, calculation or trial was performed.
26	Partly verified	Full text not readStored summary read	N26 · Evidence conditionCompany and subsidiary authorsRequired	The original Korean account states Do-Un Kim was a NEWTREE employee and Seung Un Kim was affiliated with subsidiary EVERSPRING; the complete original summary also retains the English employment/affiliation account. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Original author-specific employment, contributions, equity/other relationships, timing and disclosures remain unread; no current affiliations/relationships are certified. Existing-content review remains incomplete.	Author-specific affiliations/employment versus contributions/COI	Proposed follow-up research distinguishing author relationships and reporting roles; no new search, calculation or trial was performed.
27	Partly verified	Full text not readStored summary read	N27 · Evidence conditionDeclaration of company nonparticipationRequired	The preserved account states the paper declared that neither company participated in design, recruitment, collection, analysis or interpretation; this declaration is not new confirmation of independence. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Actual analysis/data access, author contributions, writing/publication roles and role-specific original records remain unread. Existing-content review remains incomplete.	Declared and actual roles in design, recruitment, collection, analysis and interpretation	Proposed follow-up research on declarations and individual roles; no new search, calculation or trial was performed.
28	Partly verified	Full text not readStored summary read	N28 · Harm-information gaps supplementing the efficacy tableSafety population of 80 and eventsSupplementary	Safety analysis included all 80 participants. The original account records one urticaria event judged unrelated to product, recovery without sequelae and no serious adverse event. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Group-specific safety denominators, observation windows, collection criteria, discontinuation, judgment procedures and long-term/vulnerable-population harms are unverified. No new rates, causal judgments or all-safety certification are made. Existing-content review remains incomplete.	Safety population, harms collection, original events and relatedness judgments	Proposed follow-up research on harms-reporting scope and subsequent follow-up; no new search, calculation or trial was performed.
29	Partly verified	Full text not readStored summary read	N29 · Evidence conditionOther collagen and opposing materialsRequired	Undenatured type II and ordinary hydrolyzed type I/III differ in composition; the original context mentions null trials. They do not become the selected product’s direct comparison or new reports. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Individual bibliographies, compositions, populations, timing and estimands of mentioned other trials are not linked in the current preserved summary and remain unverified. Existing-content review remains incomplete.	Other-composition trial identity and correspondence to the same formulation/question	Proposed follow-up research distinguishing applicability across compositions/results; no new search, calculation or trial was performed.
30	Partly verified	Full text not readStored summary read	N30 · Evidence conditionOther populations and long-term/clinical outcomesRequired	Original results concern the specific low-molecular-weight peptide and early knee osteoarthritis; they are not generalized to all collagen, all pain scales, advanced disease or long-term clinical outcomes. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Other preparations, disease stages, durations/doses, long-term functional/structural results and vulnerable-population materials are unverified. Existing-content review remains incomplete.	Applicability and follow-up beyond the tested preparation, population and duration	Proposed follow-up research distinguishing the selected question from other conditions; no new search, calculation or trial was performed.
31	Partly verified	Full text not readStored summary read	N31 · Evidence conditionOriginal values, axes, Korean/English and historyRequired	The complete original summary retains parent C50, B/P/R1/I0/E+/B2, unrecorded precision, three false markers, empty override reasons, Korean/English, 2026-08-26, empty corrections/deliberation and selected subclaim grade/note. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Historical cross-check/full-text-review accounts do not establish current review/reading or satisfied subclaim conditions. Absent subclaim score/status/axes and parent classification keys are not filled. Existing-content review remains incomplete.	Selected subclaim versus original parent values, reference dates and correction/history	Proposed updating research distinguishing original-material changes from preparation versions; no new search, calculation or trial was performed.
32	Partly verified	Full text not readStored summary read	N32 · Evidence conditionSummary read; external material unreadRequired	The preserved summary was read for preparation, linking Kim DU 2025 bibliography/URL with PMID40977985. External papers, registration, protocols, SAP and original funding/COI disclosures remain unread without attempted access. S01	Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Bibliography links or KCT identifiers do not upgrade external acquisition, reading or review. No separate external-link/click check is performed. Existing-content review remains incomplete.	Material-specific actual reading, identity/URL and additional-material gaps	A research proposal for scope-specific updates based on actually acquired material; no new investigation, calculation or trial is performed in this conversion.

No items match your search or filter.

32 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: Early knee osteoarthritis trial in adults with Kellgren–Lawrence grade 1–2. The 80 randomized participants, 40/40 allocation, primary efficacy PP60/80, exclusion of 20/80 (25%) and safety population of 80 are original trial context, not substitutes for exact observed/analysis denominators for selected VAS. PP KL imbalance P=.037, recruitment/baseline characteristics and outcome-specific populations remain distinct.
Ingredient, formulation and route: The specific research product was low-molecular-weight collagen peptide, 3 g daily. Detailed formulation, molecular weight, source/composition, batches and actual individual exposure are unverified. This is not transferred to effects of other compositions or all collagen, or into new intake instructions, product recommendations or treatment methods.
Dose: Original research exposure of 3 g daily for 180 days and PP inclusion criteria of at least 80% adherence and no major deviation are retained. Actual VAS assessment windows, individual exposure/adherence/discontinuation and other durations/doses are unverified. No new conversion or implementation guidance is created.
Comparator: Double-blind randomized comparison with placebo manufactured by NEWTREE. Actual placebo identity/matching, allocation/masking, accompanying pain management and VAS measurement/analysis details are unverified. The original declaration that companies did not participate in design, recruitment, collection, analysis or interpretation is retained without confirmation of actual independence.
Measured outcome: The selected reduced VAS pain question retains the original between-group P=.299 and null-result note. VAS scale range/units, exact timing, change/final values, group-specific values/effect, denominators, model, CI and prespecified hierarchy are unverified. Day-180 WOMAC change in PP60 and original approximate -2.51/P=.006 are not transferred into improved VAS pain. Nonsignificance is not converted into exact zero effect, equivalence or confirmed exclusion of important benefit.
Duration: The original context of VAS measured concurrently in a 180-day trial is distinguished from unverified exact VAS timing/estimand. The prespecified day-180 WOMAC change scope or other visit/long-term results are not assigned to VAS.
Questions outside this scope: Mixing WOMAC pain, WOMAC total and VAS scales, timing, estimands, denominators or hierarchy; Calculating new effects, CIs, final values or response rates from original ± values, P values or sample size, or relabeling original approximate -2.51/SMD as a current calculation; Using the same-direction ITT account to fill quantitative effects, significance or confirmed CI; Reusing PP60/80, exclusion of 20/80 (25%), randomized 40/40 or safety population of 80 as the same confirmed denominator for the selected outcome; Turning the 10-point WOMAC total sample-size assumption or post hoc SMD 0.46/external AAOS 0.39 into a prespecified pain/VAS success threshold; Extending positive WOMAC results to all pain scales/collagen, or converting nonsignificant VAS into exact zero effect, equivalence or certified exclusion of all important benefit; Totaling the same report/KCT, participants/groups, scales, time points or sibling sheets as new independent trials/participants; Turning product/placebo manufacture, support, company/subsidiary affiliations or nonparticipation declarations into new confirmation of independence or all detailed disclosures; Assigning parent scores/axes or historical cross-checks to subclaim scores, current review or original-material reading; New calculations, hypothetical values, effects/CIs, grades, independence certification or implementation guidance for collagen/product intake or pain/knee treatment

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Kim DU et al. 2025

PubMed

Material type: Double-blind placebo-controlled randomized trial
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: Selected VAS retains the original note of a null between-group result, P=.299. WOMAC -1.90±4.14 versus +0.61±3.97 and original approximate -2.51/P=.006 from the same evidence record are preserved context for a different outcome, not VAS values. Exact VAS timing, change/final values, denominators, group-specific values, CI and prespecified hierarchy are unverified.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 Kim DU2025/KCT0005507 concerns a double-blind placebo-controlled 180-day trial in 80 adults with Kellgren–Lawrence grade 1–2, randomized 40/40. Primary PP60/80 with exclusion of 20/80 (25%) for the specific 3-g-daily low-molecular-weight peptide is distinct from safety population of 80. Prespecified primary day-180 WOMAC pain change of -1.90±4.14 versus +0.61±3.97, approximate between-group -2.51 points/P=.006, and concurrent VAS P=.299 are different scales/results. Exact VAS timing, observed/analysis denominators, group values/CI/hierarchy are unverified in the current summary. Same-direction ITT accounts, PP KL imbalance P=.037, the 10-point WOMAC total sample-size assumption, post hoc SMD 0.46/external AAOS 0.39 and manufacturer support/author-relationship gaps are distinguished. The same report, registration, 80 participants/PP60, groups, scales, time points and sibling sheets are not totaled as new independent trials/participants. Report/material slots do not establish unique clinical-trial, participant or independent-replication totals; no new totals or independence certification are made.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only stored-summary and bibliographic content was used for production. External material verification/review is not complete.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

Report counts versus independent study counts

S01 Kim DU2025/KCT0005507 concerns a double-blind placebo-controlled 180-day trial in 80 adults with Kellgren–Lawrence grade 1–2, randomized 40/40. Primary PP60/80 with exclusion of 20/80 (25%) for the specific 3-g-daily low-molecular-weight peptide is distinct from safety population of 80. Prespecified primary day-180 WOMAC pain change of -1.90±4.14 versus +0.61±3.97, approximate between-group -2.51 points/P=.006, and concurrent VAS P=.299 are different scales/results. Exact VAS timing, observed/analysis denominators, group values/CI/hierarchy are unverified in the current summary. Same-direction ITT accounts, PP KL imbalance P=.037, the 10-point WOMAC total sample-size assumption, post hoc SMD 0.46/external AAOS 0.39 and manufacturer support/author-relationship gaps are distinguished. The same report, registration, 80 participants/PP60, groups, scales, time points and sibling sheets are not totaled as new independent trials/participants. Report/material slots do not establish unique clinical-trial, participant or independent-replication totals; no new totals or independence certification are made.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Selected question and original subclaim values

Required materials and conditions: Selected question grade/note, parent context and presence of score/status/axes
Conditions for verification: Selected question grade/note, parent context and presence of score/status/axes: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing selected question grade/note, parent context and presence of score/status/axes to link required evidence with current materials for the selected question.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

N02 · Early knee osteoarthritis population

Required materials and conditions: Actual disease stage, recruitment criteria and baseline characteristics
Conditions for verification: Actual disease stage, recruitment criteria and baseline characteristics: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing actual disease stage, recruitment criteria and baseline characteristics to link required evidence with current materials for the selected question.
Referenced methods: M03 §3.2.1; Detailed population criteria are designed by CHAMGAP; M03 §3.2.1–3.2.4; Dose, duration and effect-modification details are designed by CHAMGAP; M03 §3.2.2–3.2.3; Reverse labels and test adaptations are designed by CHAMGAP

N03 · Specific low-molecular-weight peptide

Required materials and conditions: Identity, composition and exposure of the tested preparation
Conditions for verification: Identity, composition and exposure of the tested preparation: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing identity, composition and exposure of the tested preparation to link required evidence with current materials for the selected question.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed

N04 · Placebo, manufacturing and control conditions

Required materials and conditions: Actual placebo identity, matching and accompanying conditions
Conditions for verification: Actual placebo identity, matching and accompanying conditions: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing actual placebo identity, matching and accompanying conditions to link required evidence with current materials for the selected question.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and testing adaptations are internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; CHAMGAP-specific independence/attribution conditions. Official-method sections used in this pilot do not certify all these detailed items.

N05 · Research exposure: 3 g daily for 180 days

Required materials and conditions: Original dose/duration and actual exposure/discontinuation
Conditions for verification: Original dose/duration and actual exposure/discontinuation: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing original dose/duration and actual exposure/discontinuation to link required evidence with current materials for the selected question.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed

N06 · 80 randomized; 40/40

Required materials and conditions: Allocation unit, generation/concealment and group denominators
Conditions for verification: Allocation unit, generation/concealment and group denominators: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing allocation unit, generation/concealment and group denominators to link required evidence with current materials for the selected question.
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M04 §4.6.1–4.6.2 distinguish studies from reports; cohort/outcome linkage is internally applied; M04 §4.5–4.6 cover material collection/selection; separation of access/reading and hyperlink specifications are internally designed.

N07 · Double blinding and measurement roles

Required materials and conditions: Masking of participants, clinical/research staff and outcome assessment/analysis
Conditions for verification: Masking of participants, clinical/research staff and outcome assessment/analysis: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing masking of participants, clinical/research staff and outcome assessment/analysis to link required evidence with current materials for the selected question.
Referenced methods: M08 Table 8.2.a, M03 §3.2.4; CHAMGAP adaptation; Material collection/selection principles in M04 §4.5–4.6; Separating access from reading and defining hyperlink behavior are designed by CHAMGAP

N08 · VAS pain scale

Required materials and conditions: Definition, units, range and measurement conditions of the selected VAS
Conditions for verification: Definition, units, range and measurement conditions of the selected VAS: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing definition, units, range and measurement conditions of the selected VAS to link required evidence with current materials for the selected question.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3; Question-specific outcome adaptation is Chamgap design; M08 Table 8.2.a and M03 §3.2.4; Chamgap application; M03 §3.2.4; Chamgap interpretation boundary

N09 · VAS assessment timing and change versus final values

Required materials and conditions: Actual VAS timing, change/final values and observed population
Conditions for verification: Actual VAS timing, change/final values and observed population: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing actual VAS timing, change/final values and observed population to link required evidence with current materials for the selected question.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations by question are our own design; M08 §8.2.2, M15 §15.3.1; our own application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations by study design are our own design

N10 · VAS P=.299: original null-result account

Required materials and conditions: VAS between-group testing distinguished from estimation and precision
Conditions for verification: VAS between-group testing distinguished from estimation and precision: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing vAS between-group testing distinguished from estimation and precision to link required evidence with current materials for the selected question.
Referenced methods: M15 §15.3.1–15.3.3; Chamgap application; M08 §8.2.2 and M15 §15.3.1; Chamgap application; M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; design-specific adaptation is Chamgap’s own design; M04 §4.6.3 and M15 §15.3.1–15.3.3; separation of statuses is Chamgap’s own design

N11 · VAS analysis denominators and ITT/PP

Required materials and conditions: Actual VAS analysis population and group-specific denominators
Conditions for verification: Actual VAS analysis population and group-specific denominators: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing actual VAS analysis population and group-specific denominators to link required evidence with current materials for the selected question.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

N12 · VAS important difference and success threshold

Required materials and conditions: Prespecified VAS important difference, precision and interpretation scope
Conditions for verification: Prespecified VAS important difference, precision and interpretation scope: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing prespecified VAS important difference, precision and interpretation scope to link required evidence with current materials for the selected question.
Referenced methods: M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M04 §4.6.3; custom application; M03 §3.2.4; custom extension boundary

N13 · Positive WOMAC: a separate result

Required materials and conditions: Relationship between WOMAC and VAS results/hierarchy in the same report
Conditions for verification: Relationship between WOMAC and VAS results/hierarchy in the same report: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing relationship between WOMAC and VAS results/hierarchy in the same report to link required evidence with current materials for the selected question.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.1–4.6.2 distinguish studies from reports; cohort/outcome linkage is internally applied; M08 Table 8.2.a, M04 §4.6.3; internal application.

N14 · PP 60: selection criteria

Required materials and conditions: Inclusion criteria and group-specific denominators for the primary PP efficacy population
Conditions for verification: Inclusion criteria and group-specific denominators for the primary PP efficacy population: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing inclusion criteria and group-specific denominators for the primary PP efficacy population to link required evidence with current materials for the selected question.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application.

N15 · 20/80 (25%) excluded

Required materials and conditions: Reasons, group distribution and outcome implications of efficacy exclusions
Conditions for verification: Reasons, group distribution and outcome implications of efficacy exclusions: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing reasons, group distribution and outcome implications of efficacy exclusions to link required evidence with current materials for the selected question.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application.

N16 · ITT described as the same direction

Required materials and conditions: ITT population, estimand, precision and relationship to PP
Conditions for verification: ITT population, estimand, precision and relationship to PP: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing iTT population, estimand, precision and relationship to PP to link required evidence with current materials for the selected question.
Referenced methods: M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed.

N17 · PP Kellgren–Lawrence imbalance

Required materials and conditions: Baseline disease-stage distribution and adjustment in the PP population
Conditions for verification: Baseline disease-stage distribution and adjustment in the PP population: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing baseline disease-stage distribution and adjustment in the PP population to link required evidence with current materials for the selected question.
Referenced methods: M03 §3.2.1; detailed population conditions are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application.

N18 · Co-exposure and adherence

Required materials and conditions: Pain-related co-exposure and adherence/change records
Conditions for verification: Pain-related co-exposure and adherence/change records: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing pain-related co-exposure and adherence/change records to link required evidence with current materials for the selected question.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptation are custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design

N19 · KCT and prospective registration

Required materials and conditions: Original registration identity, prespecified endpoints/analyses and changes
Conditions for verification: Original registration identity, prespecified endpoints/analyses and changes: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing original registration identity, prespecified endpoints/analyses and changes to link required evidence with current materials for the selected question.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; custom application; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

N20 · Two pain scales and prespecified hierarchy

Required materials and conditions: Prespecified endpoint, timing and multiplicity scope for WOMAC pain and VAS
Conditions for verification: Prespecified endpoint, timing and multiplicity scope for WOMAC pain and VAS: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing prespecified endpoint, timing and multiplicity scope for WOMAC pain and VAS to link required evidence with current materials for the selected question.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; internal application; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed.

N21 · Sample size: 10-point WOMAC total difference

Required materials and conditions: Sample-size planning endpoint/assumptions and selected result
Conditions for verification: Sample-size planning endpoint/assumptions and selected result: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing sample-size planning endpoint/assumptions and selected result to link required evidence with current materials for the selected question.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; internal application; M15 §15.3.1–15.3.3; internal application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed.

N22 · Post hoc SMD and external important difference

Required materials and conditions: Prespecified success threshold versus post hoc interpretation/external criteria
Conditions for verification: Prespecified success threshold versus post hoc interpretation/external criteria: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing prespecified success threshold versus post hoc interpretation/external criteria to link required evidence with current materials for the selected question.
Referenced methods: M15 §15.3.1–15.3.3; internal application; M08 Table 8.2.a, M04 §4.6.3; internal application; M03 §3.2.4; internal extension boundaries; M04 §4.5–4.6 cover material collection/selection; separation of access/reading and hyperlink specifications are internally designed.

N23 · One trial, sibling sheets and independence

Required materials and conditions: Report–trial–population–outcome relationships and independent replication materials
Conditions for verification: Report–trial–population–outcome relationships and independent replication materials: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing report–trial–population–outcome relationships and independent replication materials to link required evidence with current materials for the selected question.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application; M04 §4.6.1–4.6.2, M15 §15.3.1; custom application; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

N24 · Research and publication support

Required materials and conditions: Separate funding and research/publication support roles
Conditions for verification: Separate funding and research/publication support roles: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing separate funding and research/publication support roles to link required evidence with current materials for the selected question.
Referenced methods: Chamgap independence/attribution conditions. The referenced official method sections do not certify every detail of these items; Data collection/selection principles in M04 §4.5–4.6; Access/reading separation and hyperlink rules are Chamgap design

N25 · Product and placebo manufacturing

Required materials and conditions: Individual records of manufacturing and free-product support/batches
Conditions for verification: Individual records of manufacturing and free-product support/batches: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing individual records of manufacturing and free-product support/batches to link required evidence with current materials for the selected question.
Referenced methods: Chamgap independence/attribution conditions. The formal methods sections in this pilot do not certify all these details; M03 §§3.2.2–3.2.3; reverse-direction labels and test adaptation are Chamgap-designed; M04 §§4.5–4.6 material collection/selection principles; access/reading separation and hyperlink rules are Chamgap-designed

N26 · Company and subsidiary authors

Required materials and conditions: Author-specific affiliations/employment versus contributions/COI
Conditions for verification: Author-specific affiliations/employment versus contributions/COI: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing author-specific affiliations/employment versus contributions/COI to link required evidence with current materials for the selected question.
Referenced methods: Chamgap’s own independence/attribution conditions; official methodology sections in this pilot do not certify all these detailed items; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

N27 · Declaration of company nonparticipation

Required materials and conditions: Declared and actual roles in design, recruitment, collection, analysis and interpretation
Conditions for verification: Declared and actual roles in design, recruitment, collection, analysis and interpretation: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing declared and actual roles in design, recruitment, collection, analysis and interpretation to link required evidence with current materials for the selected question.
Referenced methods: Chamgap independence/attribution conditions. The referenced official method sections do not certify every detail of these items; Data collection/selection principles in M04 §4.5–4.6; Access/reading separation and hyperlink rules are Chamgap design

N28 · Safety population of 80 and events

Required materials and conditions: Safety population, harms collection, original events and relatedness judgments
Conditions for verification: Safety population, harms collection, original events and relatedness judgments: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Supplementary
Application exceptions: Supplement the selected subclaim’s safety-material gaps; pain-scale results or parent safety wording do not determine safety, generate harms rates or create new usage instructions.
Why this condition is needed: Preparation item distinguishing safety population, harms collection, original events and relatedness judgments to link required evidence with current materials for the selected question.
Referenced methods: M19 §19.1.2–19.2.4; detailed distinctions are Chamgap’s own design; M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Chamgap application

N29 · Other collagen and opposing materials

Required materials and conditions: Other-composition trial identity and correspondence to the same formulation/question
Conditions for verification: Other-composition trial identity and correspondence to the same formulation/question: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing other-composition trial identity and correspondence to the same formulation/question to link required evidence with current materials for the selected question.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed; M03 §3.2.2–3.2.3; reverse-direction labels and testing adaptations are internally designed; M03 §3.2.1–3.2.4; details of dose, duration and effect modification are internally designed; M04 §4.6.1–4.6.2 distinguish studies from reports; cohort/outcome linkage is internally applied.

N30 · Other populations and long-term/clinical outcomes

Required materials and conditions: Applicability and follow-up beyond the tested preparation, population and duration
Conditions for verification: Applicability and follow-up beyond the tested preparation, population and duration: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing applicability and follow-up beyond the tested preparation, population and duration to link required evidence with current materials for the selected question.
Referenced methods: M03 §3.2.1–3.2.4; Dose, duration and effect-modification details are designed by CHAMGAP; M03 §3.2.4; CHAMGAP’s boundary for extensions; M03 §3.2.1; Detailed population criteria are designed by CHAMGAP; M03 §3.2.2–3.2.3; Reverse labels and test adaptations are designed by CHAMGAP

N31 · Original values, axes, Korean/English and history

Required materials and conditions: Selected subclaim versus original parent values, reference dates and correction/history
Conditions for verification: Selected subclaim versus original parent values, reference dates and correction/history: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing selected subclaim versus original parent values, reference dates and correction/history to link required evidence with current materials for the selected question.
Referenced methods: M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed

N32 · Summary read; external material unread

Required materials and conditions: Material-specific actual reading, identity/URL and additional-material gaps
Conditions for verification: Material-specific actual reading, identity/URL and additional-material gaps: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Preparation item distinguishing material-specific actual reading, identity/URL and additional-material gaps to link required evidence with current materials for the selected question.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

What the statuses mean

Met: Status for necessary evidence confirmed after existing content review. No completion is declared in the current presentation.
Partly verified: Some information in the stored summary is linked into the table. External comparison/content review is not complete.
Unverified: The article leaves this unverified, or required material is absent from the current stored summary. This is distinct from zero, absence or safety.
Review incomplete: Existing content review remains incomplete.
Not reported: Not reported within the stored material actually read; not extended to the entire primary paper.
Inaccessible: Means an actual access failure. Access not attempted here is not assigned this state.
Not applicable: Not used as a substitute for an evidence gap.
Conflicting data: Requires an observed disagreement under the same comparison criteria; not automatically judged in this production.
Insufficient evidence for the conditions: Marks a gap in additional material required by the selected conditions; not a new efficacy grade.

Change history

2026-10-13 · Public page/material version 1.0

Public pages and materials were prepared from the existing 32 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Selected question and original subclaim values

Current findings: The original selected Reduced VAS pain subclaim, grade D and note are retained. Parent C50 and original axes concern the parent verdict.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Subclaim score, status and axes are absent; parent values are not assigned to the subclaim. Existing-content review remains incomplete.
Reason for missing information: Subclaim score, status and axes are absent; parent values are not assigned to the subclaim.
Required materials and conditions: Selected question grade/note, parent context and presence of score/status/axes
Materials to obtain first: Materials distinguishing the selected subclaim from the parent verdict
Further research: Proposed updating research linking original-question scope to additional materials; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Selected question grade/note, parent context and presence of score/status/axes: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing selected question grade/note, parent context and presence of score/status/axes to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

Related sources S01

N02 · Early knee osteoarthritis population

Current findings: The original population was 80 adults with Kellgren–Lawrence grade 1–2 early knee osteoarthritis.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Detailed eligibility, age/symptoms, baseline pain, comorbidities and group-specific characteristics are unverified. Existing-content review remains incomplete.
Reason for missing information: Detailed eligibility, age/symptoms, baseline pain, comorbidities and group-specific characteristics are unverified.
Required materials and conditions: Actual disease stage, recruitment criteria and baseline characteristics
Materials to obtain first: Recruitment/eligibility, baseline characteristics and group-specific population materials
Further research: Proposed follow-up research on applicability and heterogeneity within the same population scope; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Actual disease stage, recruitment criteria and baseline characteristics: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing actual disease stage, recruitment criteria and baseline characteristics to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.1; Detailed population criteria are designed by CHAMGAP; M03 §3.2.1–3.2.4; Dose, duration and effect-modification details are designed by CHAMGAP; M03 §3.2.2–3.2.3; Reverse labels and test adaptations are designed by CHAMGAP

Related sources S01

N03 · Specific low-molecular-weight peptide

Current findings: The specific tested low-molecular-weight collagen peptide at 3 g daily is retained; it does not become an effect of all oral collagen or other compositions.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Molecular-weight distribution, source/manufacturing, detailed composition, batches and actual individual exposure are unverified. Existing-content review remains incomplete.
Reason for missing information: Molecular-weight distribution, source/manufacturing, detailed composition, batches and actual individual exposure are unverified.
Required materials and conditions: Identity, composition and exposure of the tested preparation
Materials to obtain first: Original product-identity, composition, batch and exposure materials
Further research: Proposed follow-up research distinguishing formulation differences and result attribution; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Identity, composition and exposure of the tested preparation: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing identity, composition and exposure of the tested preparation to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed

Related sources S01

N04 · Placebo, manufacturing and control conditions

Current findings: The original double-blind placebo-controlled design and account that NEWTREE manufactured product and placebo are retained.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Placebo ingredients, sensory matching, co-exposure and equality of actual conditions between groups are unverified. Existing-content review remains incomplete.
Reason for missing information: Placebo ingredients, sensory matching, co-exposure and equality of actual conditions between groups are unverified.
Required materials and conditions: Actual placebo identity, matching and accompanying conditions
Materials to obtain first: Placebo identity, sensory matching and group-specific co-exposure materials
Further research: Proposed follow-up research on control conditions and measurement bias; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Actual placebo identity, matching and accompanying conditions: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing actual placebo identity, matching and accompanying conditions to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and testing adaptations are internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; CHAMGAP-specific independence/attribution conditions. Official-method sections used in this pilot do not certify all these detailed items.

Related sources S01

N05 · Research exposure: 3 g daily for 180 days

Current findings: The original research condition was 3 g daily for 180 days; no new intake instructions, product recommendations or treatment methods are provided.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Individual exposure, adherence measurement, discontinuation/changes and results for other durations/doses are unverified. Existing-content review remains incomplete.
Reason for missing information: Individual exposure, adherence measurement, discontinuation/changes and results for other durations/doses are unverified.
Required materials and conditions: Original dose/duration and actual exposure/discontinuation
Materials to obtain first: Research exposure, adherence, discontinuation and change records
Further research: Proposed follow-up research distinguishing dose/duration-specific applicability; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original dose/duration and actual exposure/discontinuation: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing original dose/duration and actual exposure/discontinuation to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed

Related sources S01

N06 · 80 randomized; 40/40

Current findings: Original allocation denominators of 80 participants randomized, 40 per group, are retained.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Original allocation generation/concealment, stratification, responsible roles and implementation remain unread. The two groups are not separate trials. Existing-content review remains incomplete.
Reason for missing information: Original allocation generation/concealment, stratification, responsible roles and implementation remain unread. The two groups are not separate trials.
Required materials and conditions: Allocation unit, generation/concealment and group denominators
Materials to obtain first: Allocation procedures, access permissions and analysis-population flow materials
Further research: Proposed follow-up research on allocation procedures and actual populations; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Allocation unit, generation/concealment and group denominators: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing allocation unit, generation/concealment and group denominators to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M04 §4.6.1–4.6.2 distinguish studies from reports; cohort/outcome linkage is internally applied; M04 §4.5–4.6 cover material collection/selection; separation of access/reading and hyperlink specifications are internally designed.

Related sources S01

N07 · Double blinding and measurement roles

Current findings: The original double-blind design is retained.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Role-specific masking, maintenance/unmasking, sensory matching and measurement/analysis procedures are unverified. The design label does not certify absence of actual bias. Existing-content review remains incomplete.
Reason for missing information: Role-specific masking, maintenance/unmasking, sensory matching and measurement/analysis procedures are unverified. The design label does not certify absence of actual bias.
Required materials and conditions: Masking of participants, clinical/research staff and outcome assessment/analysis
Materials to obtain first: Role-specific masking and measurement/analysis records
Further research: Proposed follow-up research on maintained masking and outcome measurement; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Masking of participants, clinical/research staff and outcome assessment/analysis: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing masking of participants, clinical/research staff and outcome assessment/analysis to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M03 §3.2.4; CHAMGAP adaptation; Material collection/selection principles in M04 §4.5–4.6; Separating access from reading and defining hyperlink behavior are designed by CHAMGAP

Related sources S01

N08 · VAS pain scale

Current findings: The selected existing question is reduced VAS pain; its subclaim grade D and note are retained. It is a different scale from WOMAC pain and WOMAC total.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. VAS form, range/score units, assessment procedures, measurement conditions and original individual data are unverified. Existing-content review remains incomplete.
Reason for missing information: VAS form, range/score units, assessment procedures, measurement conditions and original individual data are unverified.
Required materials and conditions: Definition, units, range and measurement conditions of the selected VAS
Materials to obtain first: Original VAS scale, measurement procedures and outcome-specific materials
Further research: Proposed follow-up research using the same scale and measurement scope; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Definition, units, range and measurement conditions of the selected VAS: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing definition, units, range and measurement conditions of the selected VAS to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3; Question-specific outcome adaptation is Chamgap design; M08 Table 8.2.a and M03 §3.2.4; Chamgap application; M03 §3.2.4; Chamgap interpretation boundary

Related sources S01

N09 · VAS assessment timing and change versus final values

Current findings: The original context of VAS measured concurrently in the 180-day trial is retained. The prespecified day-180 WOMAC change timing and estimand are not assigned to VAS.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Exact VAS visits/assessment windows, change versus final values, repeated measurements and group-specific observed denominators are unverified. Existing-content review remains incomplete.
Reason for missing information: Exact VAS visits/assessment windows, change versus final values, repeated measurements and group-specific observed denominators are unverified.
Required materials and conditions: Actual VAS timing, change/final values and observed population
Materials to obtain first: VAS visit/estimand definitions and observed materials
Further research: Proposed follow-up research distinguishing scales, timing and change/final values; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Actual VAS timing, change/final values and observed population: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing actual VAS timing, change/final values and observed population to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations by question are our own design; M08 §8.2.2, M15 §15.3.1; our own application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations by study design are our own design

Related sources S01

N10 · VAS P=.299: original null-result account

Current findings: The selected note and original result that the between-group comparison was null, P=.299, are retained. No new effect size, CI, exact zero effect or equivalence is created.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Group-specific VAS values, effect estimate, direction, units, CI, model and test details are unverified. Existing-content review remains incomplete.
Reason for missing information: Group-specific VAS values, effect estimate, direction, units, CI, model and test details are unverified.
Required materials and conditions: VAS between-group testing distinguished from estimation and precision
Materials to obtain first: Group-specific VAS results, between-group estimates, original model and CI materials
Further research: Proposed follow-up research distinguishing nonsignificance from uncertainty; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: VAS between-group testing distinguished from estimation and precision: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing vAS between-group testing distinguished from estimation and precision to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M15 §15.3.1–15.3.3; Chamgap application; M08 §8.2.2 and M15 §15.3.1; Chamgap application; M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; design-specific adaptation is Chamgap’s own design; M04 §4.6.3 and M15 §15.3.1–15.3.3; separation of statuses is Chamgap’s own design

Related sources S01

N11 · VAS analysis denominators and ITT/PP

Current findings: The trial randomized 80 participants and had a primary efficacy PP population of 60, but exact VAS analysis/observed denominators are separately unverified. Neither the safety population of 80 nor WOMAC PP results are automatically transferred to VAS.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. VAS group-specific PP/ITT, completed/observed denominators, exclusions, missingness handling and sensitivity analyses are unverified. Existing-content review remains incomplete.
Reason for missing information: VAS group-specific PP/ITT, completed/observed denominators, exclusions, missingness handling and sensitivity analyses are unverified.
Required materials and conditions: Actual VAS analysis population and group-specific denominators
Materials to obtain first: VAS analysis flow, group-specific denominators and missingness/sensitivity materials
Further research: Proposed follow-up research distinguishing outcome-specific populations and missingness assumptions; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Actual VAS analysis population and group-specific denominators: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing actual VAS analysis population and group-specific denominators to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

Related sources S01

N12 · VAS important difference and success threshold

Current findings: WOMAC-related post hoc SMD 0.46/external AAOS 0.39 interpretations are not transferred into a prespecified VAS success threshold or confirmation of clinical nullity.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: The currently required information is unverified in the preserved summary. Prespecified VAS important difference, estimand/CI, planned power and clinical importance are unverified. Existing-content review remains incomplete.
Reason for missing information: Prespecified VAS important difference, estimand/CI, planned power and clinical importance are unverified.
Required materials and conditions: Prespecified VAS important difference, precision and interpretation scope
Materials to obtain first: Prespecified VAS criteria/plans, between-group CI and scale correspondence
Further research: Proposed follow-up research on scale-specific important differences and uncertainty; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Prespecified VAS important difference, precision and interpretation scope: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing prespecified VAS important difference, precision and interpretation scope to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M04 §4.6.3; custom application; M03 §3.2.4; custom extension boundary

Related sources S01

N13 · Positive WOMAC: a separate result

Current findings: Prespecified day-180 WOMAC pain change in the PP population of 60 was -1.90±4.14 versus +0.61±3.97, with an original approximate between-group difference of -2.51 points/P=.006. This is not transferred into improved VAS pain.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Scale-specific analysis denominators, covariance, measurement/test correspondence and details of disagreement between results are unverified. The two scales are not counted as independent replications. Existing-content review remains incomplete.
Reason for missing information: Scale-specific analysis denominators, covariance, measurement/test correspondence and details of disagreement between results are unverified. The two scales are not counted as independent replications.
Required materials and conditions: Relationship between WOMAC and VAS results/hierarchy in the same report
Materials to obtain first: Analysis/measurement correspondence and results for the two pain scales
Further research: Proposed follow-up research distinguishing scale-specific results and disagreement; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relationship between WOMAC and VAS results/hierarchy in the same report: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing relationship between WOMAC and VAS results/hierarchy in the same report to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.1–4.6.2 distinguish studies from reports; cohort/outcome linkage is internally applied; M08 Table 8.2.a, M04 §4.6.3; internal application.

Related sources S01

N14 · PP 60: selection criteria

Current findings: The original primary efficacy population was 60/80 PP participants with at least 80% adherence and no major deviation, distinct from the safety population of 80 and randomized 40/40.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Group-specific PP denominators, time-specific observations, deviation/attrition reasons and the selected question’s actual analysis population are not verified in detail. Existing-content review remains incomplete.
Reason for missing information: Group-specific PP denominators, time-specific observations, deviation/attrition reasons and the selected question’s actual analysis population are not verified in detail.
Required materials and conditions: Inclusion criteria and group-specific denominators for the primary PP efficacy population
Materials to obtain first: Group-specific PP inclusion/exclusion, observation and deviation materials
Further research: Proposed follow-up research on differences between PP-selected and randomized populations; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Inclusion criteria and group-specific denominators for the primary PP efficacy population: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing inclusion criteria and group-specific denominators for the primary PP efficacy population to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application.

Related sources S01

N15 · 20/80 (25%) excluded

Current findings: Original exclusion of 20/80 (25%) is retained; exclusions are not all relabeled as follow-up losses or a single reason.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Group-specific adherence/deviation versus missingness/discontinuation, missingness assumptions and sensitivity results are unverified. Existing-content review remains incomplete.
Reason for missing information: Group-specific adherence/deviation versus missingness/discontinuation, missingness assumptions and sensitivity results are unverified.
Required materials and conditions: Reasons, group distribution and outcome implications of efficacy exclusions
Materials to obtain first: Group-specific exclusion reasons, observation/missingness and analysis handling
Further research: Proposed follow-up research on uncertainty under exclusion/missingness assumptions; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Reasons, group distribution and outcome implications of efficacy exclusions: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing reasons, group distribution and outcome implications of efficacy exclusions to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application.

Related sources S01

N16 · ITT described as the same direction

Current findings: The original account describes ITT only as the same direction; this does not fill equal effect sizes, significance, CI or confirmation of PP results.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Selected-outcome ITT values, group denominators, model, missingness handling and CI/P are unverified. Existing-content review remains incomplete.
Reason for missing information: Selected-outcome ITT values, group denominators, model, missingness handling and CI/P are unverified.
Required materials and conditions: ITT population, estimand, precision and relationship to PP
Materials to obtain first: Outcome-specific ITT estimates, denominators, missingness model and PP correspondence
Further research: Proposed follow-up research distinguishing different ITT/PP analysis scopes; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: ITT population, estimand, precision and relationship to PP: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing iTT population, estimand, precision and relationship to PP to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed.

Related sources S01

N17 · PP Kellgren–Lawrence imbalance

Current findings: The original account of PP Kellgren–Lawrence grade-distribution imbalance, P=.037, is retained.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Group-specific stage distributions, pain/other baseline differences, adjustment and sensitivity materials are unverified. No adjusted effect is newly calculated. Existing-content review remains incomplete.
Reason for missing information: Group-specific stage distributions, pain/other baseline differences, adjustment and sensitivity materials are unverified. No adjusted effect is newly calculated.
Required materials and conditions: Baseline disease-stage distribution and adjustment in the PP population
Materials to obtain first: PP baseline characteristics and adjustment/sensitivity materials
Further research: Proposed follow-up research on baseline imbalance and population selection; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Baseline disease-stage distribution and adjustment in the PP population: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing baseline disease-stage distribution and adjustment in the PP population to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.1; detailed population conditions are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application.

Related sources S01

N18 · Co-exposure and adherence

Current findings: The PP inclusion criterion of at least 80% adherence is distinguished from actual participant-specific adherence.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: The currently required information is unverified in the preserved summary. Concurrent analgesics, rehabilitation/activity, other supplements, rescue medication and actual adherence measurement/discontinuation are unverified. No new treatment/exercise methods are created. Existing-content review remains incomplete.
Reason for missing information: Concurrent analgesics, rehabilitation/activity, other supplements, rescue medication and actual adherence measurement/discontinuation are unverified. No new treatment/exercise methods are created.
Required materials and conditions: Pain-related co-exposure and adherence/change records
Materials to obtain first: Group-specific co-exposure, adherence, change and rescue-medication records
Further research: Proposed follow-up research on co-exposure and attribution of product results; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Pain-related co-exposure and adherence/change records: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing pain-related co-exposure and adherence/change records to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptation are custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design

Related sources S01

N19 · KCT and prospective registration

Current findings: The original registration identifier KCT0005507 and prospective-registration account are retained; identifier format is not changed and no new registration status is certified.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Registration full text, change history, protocol/SAP and comparison with actual recruitment/analysis timing remain unread. Existing-content review remains incomplete.
Reason for missing information: Registration full text, change history, protocol/SAP and comparison with actual recruitment/analysis timing remain unread.
Required materials and conditions: Original registration identity, prespecified endpoints/analyses and changes
Materials to obtain first: Original registration history, protocol and SAP
Further research: Proposed follow-up research linking prespecified plans with reported results; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original registration identity, prespecified endpoints/analyses and changes: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing original registration identity, prespecified endpoints/analyses and changes to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; custom application; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

Related sources S01

N20 · Two pain scales and prespecified hierarchy

Current findings: The prespecified primary endpoint was baseline-to-day-180 WOMAC pain change; concurrent VAS was a separate pain outcome. The original false marker for split coprimary results is not converted into a new coprimary declaration.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. VAS prespecified hierarchy, actual assessment windows, multiple outcome/time-point tests, multiplicity handling and SAP are unverified. Existing-content review remains incomplete.
Reason for missing information: VAS prespecified hierarchy, actual assessment windows, multiple outcome/time-point tests, multiplicity handling and SAP are unverified.
Required materials and conditions: Prespecified endpoint, timing and multiplicity scope for WOMAC pain and VAS
Materials to obtain first: Original endpoint hierarchy, timing and multiplicity plans
Further research: Proposed follow-up research distinguishing endpoint estimates and prespecified hierarchy; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Prespecified endpoint, timing and multiplicity scope for WOMAC pain and VAS: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing prespecified endpoint, timing and multiplicity scope for WOMAC pain and VAS to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; internal application; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed.

Related sources S01

N21 · Sample size: 10-point WOMAC total difference

Current findings: The original sample-size calculation assumed a 10-point WOMAC total difference rather than WOMAC pain; those 10 points do not become a prespecified pain-success threshold.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Planned variance, power, attrition assumptions and precision scope for pain/VAS are unverified. Existing-content review remains incomplete.
Reason for missing information: Planned variance, power, attrition assumptions and precision scope for pain/VAS are unverified.
Required materials and conditions: Sample-size planning endpoint/assumptions and selected result
Materials to obtain first: Sample-size calculation plan/assumptions and endpoint-specific precision
Further research: Proposed follow-up research on planning assumptions and actual endpoints; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Sample-size planning endpoint/assumptions and selected result: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing sample-size planning endpoint/assumptions and selected result to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; internal application; M15 §15.3.1–15.3.3; internal application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed.

Related sources S01

N22 · Post hoc SMD and external important difference

Current findings: The authors’ post hoc interpretation that observed SMD 0.46 exceeded external AAOS minimum difference 0.39 is retained as original history; the original account states no clinical-success threshold was prespecified.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. SMD definition, corresponding endpoint, denominator, CI and population/scale/applicability scope of the external criterion are unverified. No new standardized effect or success certification is made. Existing-content review remains incomplete.
Reason for missing information: SMD definition, corresponding endpoint, denominator, CI and population/scale/applicability scope of the external criterion are unverified. No new standardized effect or success certification is made.
Required materials and conditions: Prespecified success threshold versus post hoc interpretation/external criteria
Materials to obtain first: Prespecified important difference, original analysis and external-criterion correspondence
Further research: Proposed follow-up research distinguishing important differences from post hoc interpretation; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Prespecified success threshold versus post hoc interpretation/external criteria: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing prespecified success threshold versus post hoc interpretation/external criteria to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M15 §15.3.1–15.3.3; internal application; M08 Table 8.2.a, M04 §4.6.3; internal application; M03 §3.2.4; internal extension boundaries; M04 §4.5–4.6 cover material collection/selection; separation of access/reading and hyperlink specifications are internally designed.

Related sources S01

N23 · One trial, sibling sheets and independence

Current findings: The same Kim DU 2025 report, KCT0005507, 80 participants/PP60, two scales, time points and sibling sheets are not totaled as new independent trials/participants. Original R1/I0 are historical parent-verdict context.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. External comparison of actual unique trial/participant correspondence and independent replication is unverified. Existing-content review remains incomplete.
Reason for missing information: External comparison of actual unique trial/participant correspondence and independent replication is unverified.
Required materials and conditions: Report–trial–population–outcome relationships and independent replication materials
Materials to obtain first: Report/registration/population/outcome relationships and separate replication materials
Further research: Proposed follow-up research distinguishing separate evidence for the same formulation/question; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Report–trial–population–outcome relationships and independent replication materials: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing report–trial–population–outcome relationships and independent replication materials to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application; M04 §4.6.1–4.6.2, M15 §15.3.1; custom application; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

Related sources S01

N24 · Research and publication support

Current findings: The original account that NEWTREE Co., Ltd. supported research and publication is retained.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Original support contracts, amounts, individual costs/roles and disclosures remain unread; publication support does not establish every cost item was verified. Existing-content review remains incomplete.
Reason for missing information: Original support contracts, amounts, individual costs/roles and disclosures remain unread; publication support does not establish every cost item was verified.
Required materials and conditions: Separate funding and research/publication support roles
Materials to obtain first: Original research/publication support contracts, roles and disclosures
Further research: Proposed follow-up research on support roles and outcome reporting; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Separate funding and research/publication support roles: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing separate funding and research/publication support roles to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap independence/attribution conditions. The referenced official method sections do not certify every detail of these items; Data collection/selection principles in M04 §4.5–4.6; Access/reading separation and hyperlink rules are Chamgap design

Related sources S01

N25 · Product and placebo manufacturing

Current findings: The original account that NEWTREE manufactured tested product and placebo is retained.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Manufacturing/batches, supply contracts, whether provision was free and role details are unverified. Manufacturing alone does not fill free-support details. Existing-content review remains incomplete.
Reason for missing information: Manufacturing/batches, supply contracts, whether provision was free and role details are unverified. Manufacturing alone does not fill free-support details.
Required materials and conditions: Individual records of manufacturing and free-product support/batches
Materials to obtain first: Manufacturing, product/placebo supply, batches and cost materials
Further research: Proposed follow-up research distinguishing manufacturing from supply roles; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Individual records of manufacturing and free-product support/batches: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing individual records of manufacturing and free-product support/batches to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap independence/attribution conditions. The formal methods sections in this pilot do not certify all these details; M03 §§3.2.2–3.2.3; reverse-direction labels and test adaptation are Chamgap-designed; M04 §§4.5–4.6 material collection/selection principles; access/reading separation and hyperlink rules are Chamgap-designed

Related sources S01

N26 · Company and subsidiary authors

Current findings: The original Korean account states Do-Un Kim was a NEWTREE employee and Seung Un Kim was affiliated with subsidiary EVERSPRING; the complete original summary also retains the English employment/affiliation account.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Original author-specific employment, contributions, equity/other relationships, timing and disclosures remain unread; no current affiliations/relationships are certified. Existing-content review remains incomplete.
Reason for missing information: Original author-specific employment, contributions, equity/other relationships, timing and disclosures remain unread; no current affiliations/relationships are certified.
Required materials and conditions: Author-specific affiliations/employment versus contributions/COI
Materials to obtain first: Author-specific affiliation, contribution, employment and COI disclosures
Further research: Proposed follow-up research distinguishing author relationships and reporting roles; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Author-specific affiliations/employment versus contributions/COI: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing author-specific affiliations/employment versus contributions/COI to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap’s own independence/attribution conditions; official methodology sections in this pilot do not certify all these detailed items; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

Related sources S01

N27 · Declaration of company nonparticipation

Current findings: The preserved account states the paper declared that neither company participated in design, recruitment, collection, analysis or interpretation; this declaration is not new confirmation of independence.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Actual analysis/data access, author contributions, writing/publication roles and role-specific original records remain unread. Existing-content review remains incomplete.
Reason for missing information: Actual analysis/data access, author contributions, writing/publication roles and role-specific original records remain unread.
Required materials and conditions: Declared and actual roles in design, recruitment, collection, analysis and interpretation
Materials to obtain first: Role declarations, contributions and analysis/writing/publication materials
Further research: Proposed follow-up research on declarations and individual roles; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Declared and actual roles in design, recruitment, collection, analysis and interpretation: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing declared and actual roles in design, recruitment, collection, analysis and interpretation to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap independence/attribution conditions. The referenced official method sections do not certify every detail of these items; Data collection/selection principles in M04 §4.5–4.6; Access/reading separation and hyperlink rules are Chamgap design

Related sources S01

N28 · Safety population of 80 and events

Current findings: Safety analysis included all 80 participants. The original account records one urticaria event judged unrelated to product, recovery without sequelae and no serious adverse event.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Group-specific safety denominators, observation windows, collection criteria, discontinuation, judgment procedures and long-term/vulnerable-population harms are unverified. No new rates, causal judgments or all-safety certification are made. Existing-content review remains incomplete.
Reason for missing information: Group-specific safety denominators, observation windows, collection criteria, discontinuation, judgment procedures and long-term/vulnerable-population harms are unverified. No new rates, causal judgments or all-safety certification are made.
Required materials and conditions: Safety population, harms collection, original events and relatedness judgments
Materials to obtain first: Harms collection, group-specific denominators, events/discontinuation and judgment materials
Further research: Proposed follow-up research on harms-reporting scope and subsequent follow-up; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Safety population, harms collection, original events and relatedness judgments: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing safety population, harms collection, original events and relatedness judgments to link required evidence with current materials for the selected question.
Application exceptions: Supplement the selected subclaim’s safety-material gaps; pain-scale results or parent safety wording do not determine safety, generate harms rates or create new usage instructions.
Referenced methods: M19 §19.1.2–19.2.4; detailed distinctions are Chamgap’s own design; M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Chamgap application

Related sources S01

N29 · Other collagen and opposing materials

Current findings: Undenatured type II and ordinary hydrolyzed type I/III differ in composition; the original context mentions null trials. They do not become the selected product’s direct comparison or new reports.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Individual bibliographies, compositions, populations, timing and estimands of mentioned other trials are not linked in the current preserved summary and remain unverified. Existing-content review remains incomplete.
Reason for missing information: Individual bibliographies, compositions, populations, timing and estimands of mentioned other trials are not linked in the current preserved summary and remain unverified.
Required materials and conditions: Other-composition trial identity and correspondence to the same formulation/question
Materials to obtain first: Each mentioned report and composition/population-specific materials
Further research: Proposed follow-up research distinguishing applicability across compositions/results; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Other-composition trial identity and correspondence to the same formulation/question: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing other-composition trial identity and correspondence to the same formulation/question to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed; M03 §3.2.2–3.2.3; reverse-direction labels and testing adaptations are internally designed; M03 §3.2.1–3.2.4; details of dose, duration and effect modification are internally designed; M04 §4.6.1–4.6.2 distinguish studies from reports; cohort/outcome linkage is internally applied.

Related sources S01

N30 · Other populations and long-term/clinical outcomes

Current findings: Original results concern the specific low-molecular-weight peptide and early knee osteoarthritis; they are not generalized to all collagen, all pain scales, advanced disease or long-term clinical outcomes.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Other preparations, disease stages, durations/doses, long-term functional/structural results and vulnerable-population materials are unverified. Existing-content review remains incomplete.
Reason for missing information: Other preparations, disease stages, durations/doses, long-term functional/structural results and vulnerable-population materials are unverified.
Required materials and conditions: Applicability and follow-up beyond the tested preparation, population and duration
Materials to obtain first: Additional population, preparation, duration and long-term clinical/harms materials
Further research: Proposed follow-up research distinguishing the selected question from other conditions; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Applicability and follow-up beyond the tested preparation, population and duration: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing applicability and follow-up beyond the tested preparation, population and duration to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.1–3.2.4; Dose, duration and effect-modification details are designed by CHAMGAP; M03 §3.2.4; CHAMGAP’s boundary for extensions; M03 §3.2.1; Detailed population criteria are designed by CHAMGAP; M03 §3.2.2–3.2.3; Reverse labels and test adaptations are designed by CHAMGAP

Related sources S01

N31 · Original values, axes, Korean/English and history

Current findings: The complete original summary retains parent C50, B/P/R1/I0/E+/B2, unrecorded precision, three false markers, empty override reasons, Korean/English, 2026-08-26, empty corrections/deliberation and selected subclaim grade/note.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Historical cross-check/full-text-review accounts do not establish current review/reading or satisfied subclaim conditions. Absent subclaim score/status/axes and parent classification keys are not filled. Existing-content review remains incomplete.
Reason for missing information: Historical cross-check/full-text-review accounts do not establish current review/reading or satisfied subclaim conditions. Absent subclaim score/status/axes and parent classification keys are not filled.
Required materials and conditions: Selected subclaim versus original parent values, reference dates and correction/history
Materials to obtain first: Original verdict, correction/change text and user comments
Further research: Proposed updating research distinguishing original-material changes from preparation versions; no new search, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Selected subclaim versus original parent values, reference dates and correction/history: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing selected subclaim versus original parent values, reference dates and correction/history to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed

Related sources S01

N32 · Summary read; external material unread

Current findings: The preserved summary was read for preparation, linking Kim DU 2025 bibliography/URL with PMID40977985. External papers, registration, protocols, SAP and original funding/COI disclosures remain unread without attempted access.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information is recorded; detailed original materials are unread and content review is incomplete. Bibliography links or KCT identifiers do not upgrade external acquisition, reading or review. No separate external-link/click check is performed. Existing-content review remains incomplete.
Reason for missing information: Bibliography links or KCT identifiers do not upgrade external acquisition, reading or review. No separate external-link/click check is performed.
Required materials and conditions: Material-specific actual reading, identity/URL and additional-material gaps
Materials to obtain first: Original paper, registration/plans, individual disclosures and user comments
Further research: A research proposal for scope-specific updates based on actually acquired material; no new investigation, calculation or trial is performed in this conversion.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Material-specific actual reading, identity/URL and additional-material gaps: the corresponding original materials/analysis scope must be available and unverified matters distinguishable. Existing wording is linked here; content review remains incomplete.
Why this condition is needed: Preparation item distinguishing material-specific actual reading, identity/URL and additional-material gaps to link required evidence with current materials for the selected question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01